Firm Logo

Depo-Provera and Brain Tumors: What Women Should Know About the Lawsuits in 2026

Depo-Provera and Brain Tumors What Women Should Know About the Lawsuits in 2026.jpgDepo-Provera and Brain Tumors What Women Should Know About the Lawsuits in 2026.jpg

You may have received Depo-Provera injections for years without knowing that researchers were investigating a possible connection between the birth control medication and certain brain tumors.

Then you were diagnosed with a meningioma.

Now you're wondering whether the injections played a role in your diagnosis, why you weren't warned about the potential risk, and whether you can pursue legal action.

Thousands of women have filed lawsuits alleging that Depo-Provera contributed to the development of meningiomas. In 2026, the litigation reached a significant turning point when Pfizer and attorneys representing plaintiffs reached a settlement agreement intended to resolve many pending claims.

But the settlement does not cover every case, and important legal questions remain for women who have already filed lawsuits and those who are only now learning about the potential connection.

Understanding the current litigation, what the settlement means, and what evidence matters can help you determine whether you have grounds to investigate a mass tort claim.

What Is the Connection Between Depo-Provera and Brain Tumors?

Depo-Provera is an injectable contraceptive containing medroxyprogesterone acetate, a synthetic form of the hormone progesterone. It is typically administered every three months to help prevent pregnancy.

Studies have found an association between prolonged use of certain progestogen medications, including injectable medroxyprogesterone acetate, and an increased risk of meningiomas. These findings have raised concerns about the potential risks of long-term Depo-Provera use.

A meningioma is a tumor that develops in the membranes surrounding the brain or spinal cord.

Many meningiomas are noncancerous and grow slowly. But that does not mean they are harmless. Depending on their size and location, they can place pressure on nearby brain structures and cause serious neurological complications.

Symptoms can include:

  • Persistent or worsening headaches
  • Changes in vision
  • Seizures
  • Weakness or numbness
  • Problems with memory, balance, or concentration

Some tumors require surgery, radiation therapy, or ongoing monitoring.

If you have been diagnosed with a meningioma and are still receiving Depo-Provera injections, speak with your healthcare provider promptly about your medication. The FDA-approved labeling instructs healthcare providers to discontinue Depo-Provera when a meningioma is diagnosed.

Has the FDA Warned About Meningioma Risks From Depo-Provera?

Yes. In December 2025, the FDA approved updated prescribing information for Depo-Provera that includes a warning about meningiomas.

The updated FDA-approved labeling addresses meningiomas reported with medroxyprogesterone acetate use, particularly following long-term exposure.

This development matters because many women received Depo-Provera injections before the meningioma warning appeared in the medication's U.S. labeling.

The warning does not mean everyone who used Depo-Provera will develop a tumor or that the medication caused every meningioma diagnosed in a former user.

For women who developed meningiomas after receiving the injections, though, the updated safety information raises questions about what the manufacturer knew, when it knew it, and whether adequate warnings should have been provided earlier.

What Is Happening With the Depo-Provera Lawsuits in November 2026?

Thousands of Depo-Provera lawsuits have been consolidated in federal multidistrict litigation, known as MDL No. 3140, in the U.S. District Court for the Northern District of Florida.

The lawsuits involve allegations that Depo-Provera and related injectable medications contributed to intracranial meningiomas and that the manufacturers failed to provide adequate warnings.

Multidistrict litigation allows related cases to be coordinated for pretrial proceedings. It is not the same as a class action, and each person's claim retains its individual circumstances.

In June 2026, plaintiffs' leadership announced a settlement with Pfizer-related defendants intended to resolve a substantial portion of the pending federal litigation. The parties subsequently entered into a confidential settlement agreement dated July 22, 2026.

According to federal court records, the registration deadline for eligible participants in the settlement program is November 30, 2026.

That deadline applies to the existing settlement program. It is not a universal deadline for everyone who used Depo-Provera to file a new lawsuit.

The settlement has specific eligibility requirements and does not resolve every claim. Plaintiffs who choose not to participate, as well as certain plaintiffs who are ineligible for the settlement, can continue pursuing their cases under the court's procedures.

The defendants have not admitted wrongdoing or liability through the settlement.

Can You Still File a Depo-Provera Lawsuit in 2026?

Yes. If you were diagnosed with a meningioma after using Depo-Provera but have not filed a lawsuit, you may still have legal options.

The 2026 settlement does not prevent new lawsuits from being filed. But the existing settlement program has separate eligibility requirements, and filing a new claim does not automatically qualify you to participate.

Whether you can pursue legal action depends on your medication history, diagnosis, applicable filing deadlines, and individual circumstances.

An attorney can review your situation, determine which legal options may be available, and explain the deadlines that apply to your potential claim.

Who Can File a Depo-Provera Brain Tumor Lawsuit?

If you received Depo-Provera injections and were later diagnosed with a meningioma, your medication history and medical evidence are central to determining whether you have grounds for a pharmaceutical product liability claim.

An attorney evaluating a potential case will generally want to understand:

  • How long you used Depo-Provera and approximately when you received the injections
  • Whether your diagnosis involves an intracranial meningioma
  • When the tumor was first identified
  • Whether you required surgery, radiation therapy, or other treatment
  • Whether the available medical and scientific evidence supports a connection between the medication and your condition

But receiving Depo-Provera injections and subsequently developing a meningioma does not automatically establish that the medication caused the tumor or that the manufacturer is legally responsible.

At Sadaka Law, founding attorney Mark T. Sadaka brings a background in law, public health, and toxicology to pharmaceutical injury litigation. That combination is particularly relevant when evaluating claims involving years of medication use, a later medical diagnosis, and questions about whether adequate safety warnings were provided.

What if You Stopped Using Depo-Provera Years Before Your Diagnosis?

A past history of Depo-Provera use can still be relevant when evaluating a potential claim.

Meningiomas often grow slowly, and a diagnosis can occur years after someone stopped receiving injections.

For example, you might have used Depo-Provera throughout your twenties or thirties but only discovered a meningioma after experiencing headaches, vision changes, or other symptoms years later.

A delay between medication use and diagnosis does not automatically rule out a claim. An attorney would need to examine the treatment history, medical evidence, and applicable filing deadlines to determine what legal options remain available.

What Records Do You Need for a Depo-Provera Lawsuit?

If you were diagnosed with a meningioma after using Depo-Provera, preserving records of your medication history and diagnosis can help establish what happened.

Important documentation can include:

  • Pharmacy or healthcare provider records showing Depo-Provera injections
  • Medical records identifying when your meningioma was diagnosed
  • MRI or CT imaging reports
  • Surgical reports, pathology findings, and treatment records
  • Documentation of medical expenses, missed work, or continuing limitations

If you no longer have records of your injections, your former healthcare provider, clinic, pharmacy, or insurer might still have information that helps establish when and how long you received the medication.

These records give an attorney a clearer picture of your treatment history, diagnosis, and the consequences of your injury.

What Compensation Could Be Available in a Depo-Provera Lawsuit?

Depending on the circumstances and applicable law, compensation in a successful Depo-Provera claim can address medical expenses, lost income, reduced earning capacity, pain and suffering, and other injury-related losses.

For someone who required brain surgery or continues to experience neurological limitations, the extent of those losses can be significant. The value of an individual claim depends on the evidence supporting liability and the specific harm involved.

The existing Depo-Provera settlement program has confidential terms, and no particular settlement amount is guaranteed. A meningioma diagnosis alone does not establish eligibility or entitlement to compensation.

Speak With Sadaka Law About a Potential Depo-Provera Claim

If you believe your meningioma diagnosis is connected to past Depo-Provera use, understanding your legal options is an important next step.

Based in New Jersey and representing clients nationally, Sadaka Law handles complex claims involving dangerous medications, defective products, and serious injuries.

Contact Sadaka Law to discuss your diagnosis, medication history, and whether you have grounds to pursue a claim.

Disclaimer: This blog is provided for informational purposes only and should not be construed as legal advice. Reading this content does not create an attorney-client relationship. For guidance regarding your specific legal matter, please contact Sadaka Law directly to discuss your situation.